Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden

Journal of Medical Economics

Volumn 18, Issue 7, 2015, Pages 492-501

  Hofmarcher, Thomas ^a,b   Borg, Sixten ^c,d  

^a LUND UNIVERSITY   (Sweden)

^b SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d EVIDERA   (United Kingdom)

Author keywords

Chronic heart failure; Costeffectiveness analysis; Ferric carboxymaltose; Healthcare costs; Iron deficiency

Indexed keywords

FERRIC CARBOXYMALTOSE; PLACEBO; FERRIC ION; IRON; MALTOSE;

AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE; HEALTH CARE COST; HEART FAILURE; HOSPITAL CARE; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; REFERENCE VALUE; SWEDEN; ANALOGS AND DERIVATIVES; CHRONIC DISEASE; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEFICIENCY; DOUBLE BLIND PROCEDURE; ECONOMICS; HEALTH SERVICE; HOSPITAL PATIENT; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OUTPATIENT; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; UTILIZATION;

ADMINISTRATION, INTRAVENOUS; AGED; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; FERRIC COMPOUNDS; HEALTH SERVICES; HEART FAILURE; HUMANS; INPATIENTS; IRON; MALE; MALTOSE; MIDDLE AGED; MODELS, ECONOMETRIC; OUTPATIENTS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; SWEDEN;

EID: 84942741574     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1029491     Document Type: Article

References (33)

1. Zarrinkoub R, Wettermark B, Wandell P, et al. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail 2013;15:995-1002
2. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005;365:1877-89
3. Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002;23:1867-76
4. Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002;87: 235-41
5. Gaviria M, Pliskin N, Kney A. Cognitive impairment in patients with advanced heart failure and its implications on decision-making capacity. Congest Heart Fail 2011;17:175-9
6. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818-27
7. Macdougall IC, Canaud B, de Francisco AL, et al. Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail 2012;14:882-6
8. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872-80
9. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;165:575-82 e3
10. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847
11. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48
12. Anker SD, Colet JC, Filippatos G, et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009;11:1084-91
13. Anell A, Glenngard AH, Merkur S. Sweden: health system review. Health Syst Transit 2012;14:1-159
14. Agvall B, Borgquist L, Foldevi M, et al. Cost of heart failure in Swedish primary healthcare. Scand J Prim Health Care 2005;23:227-32
15. Cline CM, Boman K, Holst M, et al. The management of heart failure in Sweden. Eur J Heart Fail 2002;4:373-6
16. Dental and Pharmaceutical Benefits Agency (Tandvårds-och läkemedelsförmånsverket-TLV). Beslut-Ferinject. Stockholm: TLV, 2008
17. Gutzwiller FS, Schwenkglenks M, Blank PR, et al. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. Eur J Heart Fail 2012;14:782-90
18. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36(11):657-68
19. Vasko P, Jonsson A, Dahlström U, et al. Arsrapport RiksSvikt-2013 ars resultat. Uppsala: Uppsala Clinical Research Center, 2014
20. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
21. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure 2014;1:52-8
22. Agvall B, Alehagen U, Dahlstrom U. The benefits of using a heart failure management programme in Swedish primary healthcare. Eur J Heart Fail 2013;15:228-36
23. The National Board of Health and Welfare (Socialstyrelsen). Statistikdatabas för diagnoser i sluten vård. Stockholm: Socialstyrelsen. Available at: http://www.socialstyrelsen.se/statistik/statistikdatabas/diagnoserislutenvard. Accessed December 22, 2014
24. Mentz RJ, Cotter G, Cleland JG, et al. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail 2014;16:614-24
25. Board of the Southern Health Care Region (Södra Regionvårdsnämnden). Regionala priser och ersättningar för Södra sjukvårdsregionen 2014. Lund: Södra Regionvårdsnämnden, 2013
26. Swedish Medicines Information Engine (FASS). Ferinject. Stockholm: Läkemedelsindustriföreningen. Available at: http://www.fass.se/LIF/product?userType0&nplId20060429000016. Accessed September 22, 2014
27. Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002;4:361-71
28. Rocca HP, Crijns HJ. Iron i.v. in heart failure: ready for implementation? Eur Heart J 2015;36:645-7
29. Silverberg DS, Iaina A, Schwartz D, et al. Intravenous iron in heart failure: beyond targeting anemia. Curr Heart Fail Rep 2011;8:14-21
30. van Veldhuisen DJ, Anker SD, Ponikowski P, et al. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 2011;8:485-93
31. Macdougall IC. Evolution of iv iron compounds over the last century. J Ren Care 2009;35(2 Suppl):8-13
32. Avni T, Leibovici L, Gafter-Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and metaanalysis. Eur J Heart Fail 2012;14:423-9
33. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics- 2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215